Azvudine efficacy in reducing mortality in COVID-19 patients

DOI record: { "DOI": "10.1186/s40001-024-02220-9", "ISSN": [ "2047-783X" ], "URL": "http://dx.doi.org/10.1186/s40001-024-02220-9", "alternative-id": [ "2220" ], "article-number": "625", "assertion": [ { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Received", "name": "received", "order": 1, "value": "24 March 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "14 December 2024" }, { "group": { "label": "Article History", "name": "ArticleHistory" }, "label": "First Online", "name": "first_online", "order": 3, "value": "26 December 2024" }, { "group": { "label": "Declarations", "name": "EthicsHeading" }, "name": "Ethics", "order": 1 }, { "group": { "label": "Ethics approval and consent to participate", "name": "EthicsHeading" }, "name": "Ethics", "order": 2, "value": "There was no direct patient involvement in the conception, design, or implementation of this study. The requirement for patient consent was waived for this retrospective study, which utilized data from electronic medical records. This study was approved by the Ethics Committee of the First Affiliated Hospital of the Gannan Medical University Hospital (LLSL-2024065)." }, { "group": { "label": "Consent for publication", "name": "EthicsHeading" }, "name": "Ethics", "order": 3, "value": "Not applicable." }, { "group": { "label": "Competing interests", "name": "EthicsHeading" }, "name": "Ethics", "order": 4, "value": "The authors declare no competing interests." } ], "author": [ { "affiliation": [], "family": "Zhong", "given": "Zhen", "sequence": "first" }, { "affiliation": [], "family": "Liu", "given": "Xiao-feng", "sequence": "additional" }, { "affiliation": [], "family": "Zhou", "given": "Xiao-zhong", "sequence": "additional" }, { "affiliation": [], "family": "Zhong", "given": "Jia-ning", "sequence": "additional" }, { "affiliation": [], "family": "Zhou", "given": "Li-cheng", "sequence": "additional" }, { "affiliation": [], "family": "Li", "given": "Rong", "sequence": "additional" }, { "affiliation": [], "family": "Liu", "given": "Xian-fa", "sequence": "additional" } ], "container-title": "European Journal of Medical Research", "container-title-short": "Eur J Med Res", "content-domain": { "crossmark-restriction": false, "domain": [ "link.springer.com" ] }, "created": { "date-parts": [ [ 2024, 12, 26 ] ], "date-time": "2024-12-26T08:39:39Z", "timestamp": 1735202379000 }, "deposited": { "date-parts": [ [ 2024, 12, 26 ] ], "date-time": "2024-12-26T09:05:31Z", "timestamp": 1735203931000 }, "funder": [ { "award": [ "202310802" ], "name": "Health Commission of Jiangxi Province,China江西省卫生健康委员会" }, { "DOI": "10.13039/501100004479", "award": [ "82060363" ], "doi-asserted-by": "publisher", "id": [ { "asserted-by": "publisher", "id": "10.13039/501100004479", "id-type": "DOI" } ], "name": "Natural Science Foundation of Jiangxi Province" }, { "award": [ "XN202023" ], "name": "Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases,Ministry of Education" } ], "indexed": { "date-parts": [ [ 2024, 12, 27 ] ], "date-time": "2024-12-27T05:18:17Z", "timestamp": 1735276697716, "version": "3.32.0" }, "is-referenced-by-count": 0, "issue": "1", "issued": { "date-parts": [ [ 2024, 12, 26 ] ] }, "journal-issue": { "issue": "1", "published-online": { "date-parts": [ [ 2024, 12 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 12, 26 ] ], "date-time": "2024-12-26T00:00:00Z", "timestamp": 1735171200000 } }, { "URL": "https://creativecommons.org/licenses/by-nc-nd/4.0", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 12, 26 ] ], "date-time": "2024-12-26T00:00:00Z", "timestamp": 1735171200000 } } ], "link": [ { "URL": "https://link.springer.com/content/pdf/10.1186/s40001-024-02220-9.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/article/10.1186/s40001-024-02220-9/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://link.springer.com/content/pdf/10.1186/s40001-024-02220-9.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "prefix": "10.1186", "published": { "date-parts": [ [ 2024, 12, 26 ] ] }, "published-online": { "date-parts": [ [ 2024, 12, 26 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "DOI": "10.1056/NEJMc2206277", "author": "AM Morris", "doi-asserted-by": "publisher", "first-page": "474", "issue": "5", "journal-title": "N Engl J Med", "key": "2220_CR1", "unstructured": "Morris AM, Lee TC. Nirmatrelvir for nonhospitalized adults with Covid-19. N Engl J Med. 2022;387(5):474–5. https://doi.org/10.1056/NEJMc2206277.", "volume": "387", "year": "2022" }, { "DOI": "10.3390/vaccines10101731", "author": "I Gentile", "doi-asserted-by": "publisher", "first-page": "1731", "issue": "10", "journal-title": "Vaccines", "key": "2220_CR2", "unstructured": "Gentile I, et al. Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a real-life study. Vaccines. 2022;10(10):1731. https://doi.org/10.3390/vaccines10101731.", "volume": "10", "year": "2022" }, { "DOI": "10.1016/S0140-6736(22)01586-0", "author": "CKH Wong", "doi-asserted-by": "publisher", "first-page": "1213", "issue": "10359", "journal-title": "Lancet (London, England)", "key": "2220_CR3", "unstructured": "Wong CKH, et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet (London, England). 2022;400(10359):1213–22. https://doi.org/10.1016/S0140-6736(22)01586-0.", "volume": "400", "year": "2022" }, { "DOI": "10.1136/bmj-2022-074572", "author": "Y Xie", "doi-asserted-by": "publisher", "first-page": "e074572", "journal-title": "BMJ", "key": "2220_CR4", "unstructured": "Xie Y, et al. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023;381:e074572. https://doi.org/10.1136/bmj-2022-074572.", "volume": "381", "year": "2023" }, { "DOI": "10.1038/s41392-021-00835-6", "author": "J-L Zhang", "doi-asserted-by": "publisher", "first-page": "414", "issue": "1", "journal-title": "Signal Transduct Target Ther", "key": "2220_CR5", "unstructured": "Zhang J-L, et al. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther. 2021;6(1):414. https://doi.org/10.1038/s41392-021-00835-6.", "volume": "6", "year": "2021" }, { "DOI": "10.1007/s15010-023-02028-5", "author": "P Bertuccio", "doi-asserted-by": "publisher", "first-page": "1633", "issue": "6", "journal-title": "Infection", "key": "2220_CR6", "unstructured": "Bertuccio P, et al. The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study. Infection. 2023;51(6):1633–44. https://doi.org/10.1007/s15010-023-02028-5.", "volume": "51", "year": "2023" }, { "DOI": "10.1001/jamanetworkopen.2023.14393", "author": "DTW Lui", "doi-asserted-by": "publisher", "first-page": "e2314393", "issue": "5", "journal-title": "JAMA Netw Open", "key": "2220_CR7", "unstructured": "Lui DTW, et al. Analysis of all-cause hospitalization and death among nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir or nirmatrelvir-ritonavir during the omicron wave in Hong Kong. JAMA Netw Open. 2023;6(5):e2314393. https://doi.org/10.1001/jamanetworkopen.2023.14393.", "volume": "6", "year": "2023" }, { "DOI": "10.1056/NEJMoa2118542", "author": "J Hammond", "doi-asserted-by": "publisher", "first-page": "1397", "issue": "15", "journal-title": "N Engl J Med", "key": "2220_CR8", "unstructured": "Hammond J, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–408. https://doi.org/10.1056/NEJMoa2118542.", "volume": "386", "year": "2022" }, { "DOI": "10.1016/j.biopha.2023.114367", "author": "SMR Hashemian", "doi-asserted-by": "publisher", "first-page": "114367", "journal-title": "Biomed Pharmacother Biomedecine & Pharmacotherapie", "key": "2220_CR9", "unstructured": "Hashemian SMR, et al. Paxlovid (Nirmatrelvir/Ritonavir): a new approach to Covid-19 therapy? Biomed Pharmacother Biomedecine & Pharmacotherapie. 2023;162:114367. https://doi.org/10.1016/j.biopha.2023.114367.", "volume": "162", "year": "2023" }, { "DOI": "10.1056/NEJMoa2116044", "author": "A Jayk Bernal", "doi-asserted-by": "publisher", "first-page": "509", "issue": "6", "journal-title": "N Engl J Med", "key": "2220_CR10", "unstructured": "Jayk Bernal A, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509–20. https://doi.org/10.1056/NEJMoa2116044.", "volume": "386", "year": "2022" }, { "DOI": "10.1038/s41594-021-00651-0", "author": "F Kabinger", "doi-asserted-by": "publisher", "first-page": "740", "issue": "9", "journal-title": "Nat Struct Mol Biol", "key": "2220_CR11", "unstructured": "Kabinger F, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740–6. https://doi.org/10.1038/s41594-021-00651-0.", "volume": "28", "year": "2021" }, { "DOI": "10.1093/infdis/jiab247", "author": "S Zhou", "doi-asserted-by": "publisher", "first-page": "415", "issue": "3", "journal-title": "J Infect Dis", "key": "2220_CR12", "unstructured": "Zhou S, et al. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to Mammalian cells. J Infect Dis. 2021;224(3):415–9. https://doi.org/10.1093/infdis/jiab247.", "volume": "224", "year": "2021" }, { "DOI": "10.1038/s41392-020-00351-z", "author": "B Yu", "doi-asserted-by": "publisher", "first-page": "236", "issue": "1", "journal-title": "Signal Transduction Targeted Therapy", "key": "2220_CR13", "unstructured": "Yu B, Chang J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. Signal Transduction Targeted Therapy. 2020;5(1):236. https://doi.org/10.1038/s41392-020-00351-z.", "volume": "5", "year": "2020" }, { "DOI": "10.1038/s41579-021-00630-8", "author": "H Yang", "doi-asserted-by": "publisher", "first-page": "685", "issue": "11", "journal-title": "Nat Rev Microbiol", "key": "2220_CR14", "unstructured": "Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. 2021;19(11):685–700. https://doi.org/10.1038/s41579-021-00630-8.", "volume": "19", "year": "2021" }, { "DOI": "10.1002/advs.202001435", "author": "Z Ren", "doi-asserted-by": "publisher", "first-page": "e2001435", "issue": "19", "journal-title": "Adv Sci", "key": "2220_CR15", "unstructured": "Ren Z, et al. A Randomized, open-label, controlled clinical trial of azvudine tablets in the treatment of mild and common COVID-19, a pilot study. Adv Sci. 2020;7(19):e2001435. https://doi.org/10.1002/advs.202001435.", "volume": "7", "year": "2020" }, { "DOI": "10.3389/fphar.2023.1228548", "author": "K-W Zhu", "doi-asserted-by": "publisher", "first-page": "24", "issue": "1228548", "journal-title": "Front Pharmacol", "key": "2220_CR16", "unstructured": "Zhu K-W. Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials. Front Pharmacol. 2023;14(1228548):24. https://doi.org/10.3389/fphar.2023.1228548.", "volume": "14", "year": "2023" }, { "DOI": "10.1038/s41598-024-74502-5", "author": "H Xie", "doi-asserted-by": "publisher", "first-page": "23974", "journal-title": "Sci Rep", "key": "2220_CR17", "unstructured": "Xie H, Wang Y, Xu Y, et al. Effectiveness and safety of azvudine versus nirmatrelvir-ritonavir in adult patients infected with COVID-19 omicron strains: a retrospective study in Beijing. Sci Rep. 2024;14:23974. https://doi.org/10.1038/s41598-024-74502-5.", "volume": "14", "year": "2024" }, { "DOI": "10.3760/cma.j.issn.1674-2397.2023.01.001", "doi-asserted-by": "publisher", "key": "2220_CR18", "unstructured": "National Health Commission of the People’s Republic of China. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 10). Chin J Clin Infect Dis. 2023; 16(01): 1–9. https://doi.org/10.3760/cma.j.issn.1674-2397.2023.01.001." }, { "DOI": "10.1016/j.eclinm.2023.101981", "author": "Y Sun", "doi-asserted-by": "publisher", "first-page": "101981", "journal-title": "EClinicalMedicine", "key": "2220_CR19", "unstructured": "Sun Y, et al. Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study. EClinicalMedicine. 2023;59:101981. https://doi.org/10.1016/j.eclinm.2023.101981.", "volume": "59", "year": "2023" }, { "DOI": "10.1007/s40121-023-00845-7", "author": "Q Zhao", "doi-asserted-by": "publisher", "first-page": "2087", "issue": "8", "journal-title": "Infect Dis Therapy", "key": "2220_CR20", "unstructured": "Zhao Q, et al. Is azvudine comparable to nirmatrelvir-ritonavir in real-world efficacy and safety for hospitalized patients with COVID-19? A retrospective cohort study. Infect Dis Therapy. 2023;12(8):2087–102. https://doi.org/10.1007/s40121-023-00845-7.", "volume": "12", "year": "2023" }, { "DOI": "10.3389/fmed.2023.1143485", "author": "RM da Silva", "doi-asserted-by": "publisher", "first-page": "1143485", "journal-title": "Front Med", "key": "2220_CR21", "unstructured": "da Silva RM, et al. Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. Front Med. 2023;10:1143485. https://doi.org/10.3389/fmed.2023.1143485.", "volume": "10", "year": "2023" }, { "DOI": "10.1002/jmv.28756", "author": "G Deng", "doi-asserted-by": "publisher", "first-page": "e28756", "issue": "4", "journal-title": "J Med Virol", "key": "2220_CR22", "unstructured": "Deng G, et al. Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a retrospective cohort study. J Med Virol. 2023;95(4):e28756. https://doi.org/10.1002/jmv.28756.", "volume": "95", "year": "2023" }, { "DOI": "10.1186/s12985-024-02316-y", "author": "Y Wang", "doi-asserted-by": "publisher", "first-page": "46", "issue": "1", "journal-title": "Virol J", "key": "2220_CR23", "unstructured": "Wang Y, et al. Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis. Virol J. 2024;21(1):46. https://doi.org/10.1186/s12985-024-02316-y.", "volume": "21", "year": "2024" }, { "DOI": "10.1021/acs.accounts.1c00697", "author": "J Chang", "doi-asserted-by": "publisher", "first-page": "565", "issue": "4", "journal-title": "Acc Chem Res", "key": "2220_CR24", "unstructured": "Chang J. 4’-modified nucleosides for antiviral drug discovery: achievements and perspectives. Acc Chem Res. 2022;55(4):565–78. https://doi.org/10.1021/acs.accounts.1c00697.", "volume": "55", "year": "2022" }, { "DOI": "10.1016/j.jinf.2021.05.008", "doi-asserted-by": "publisher", "key": "2220_CR25", "unstructured": "Wang, Yaqi, et al. Efficacy and safety of azvudine for the treatment of COVID-19: a multicenter, open-label, randomized controlled trial. J Infect. 2021;83(3): 346–355. https://doi.org/10.1016/j.jinf.2021.05.008." } ], "reference-count": 25, "references-count": 25, "relation": {}, "resource": { "primary": { "URL": "https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-024-02220-9" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Azvudine efficacy in reducing mortality in COVID-19 patients", "type": "journal-article", "update-policy": "https://doi.org/10.1007/springer_crossmark_policy", "volume": "29" }